S2
. HRMS ESI spectrum of CGKRK pentapeptide S3 Figure S2 . MALDI mass spectrum of CGKRK pentapeptide S4 Figure S3 . 1 H-NMR spectrum of CGKRK S5 Figure S4 . HPLC Chromatograms of CGKRK pentapeptide using Mobile Phases S6 Figure S5 . The X-ray diffraction (XRD) pattern of Au-CGKRK conjugate S7 Figure S6 . siRNA binding properties of the Au-CGKRK nanoconjugates S8
and bare AuNPs Figure S8 . Intraperitoneally administered only STAT3siRNA, or only PD-L1siRNA in complexation with Au-CGKRK nanoconjugates are therapeutically less efficient (including less overall survivability) than when they are administered simultaneously (Fig. 9) . a. Relative tumor growth inhibition profiles observed in tumor bearing mice (n = 5) i.p. treated with: 5% aqueous glucose UT (pink); Au-CGKRK+scr.siRNA (red); Au-CGKRK+PD-L1siRNA (green) and 
